HOT NEWS
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon » Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trial...
Nycomed on track in 2009 with strong growth in Key Products » Nycomed was on track in 2009, with strong growth in Key Products and most emerging markets. Pantopra...
Bayer Successful in a Difficult Environment » 2009 was operationally one of the strongest years for the Bayer Group. "We were successful in a diff...
Phase III study of Avastin in advanced stomach cancer did not meet primary endpo... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the topline results from a global phase III trial inves...
Sanofi Pasteur's A(H1N1) Vaccine HUMENZA®* Recommended by European Medicines Ag... » Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announc...
FY2009: Merck KGaA Revenues Rise by 2.1% to € 7.7 Billion » Merck KGaA announced that Group total revenues rose 2.1% in 2009 - meeting the guidance given earlie...
GSK receives positive opinions in Europe for Tyverb® and Votrient™ » GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Product...
My child matters Supports Seven New Childhood Cancer Care Projects » On the International Childhood Cancer Day, the International Union Against Cancer (UICC) and sanofi-...
Abbott Completes Acquisition of Solvay Pharmaceuticals » Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisit...
Merck Receives European Approval for ELONVA® (corifollitropin alfa injection) » Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European C...
Abbott
AbbottAbbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. For more information, please visit http://www.abbott.com

Abbott RSS Channel
Filter     Display # 
# Article Title Hits
1 Abbott Completes Acquisition of Solvay Pharmaceuticals 385
2 Monoclonal Antibody Adds Early-Stage Biologic to Abbott's Oncology Pipeline 478
3 Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes 756
4 Abbott to Acquire Solvay Pharmaceuticals Business 934
5 Abbott to Acquire Visiogen, Expanding Vision Care Portfolio 459
6 Abbott Reports Strong Second Quarter Results 428
7 Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent 623
8 Abbott's XIENCE V(R) Demonstrates Impressive Results in SPIRIT V Study 707
9 New data to be presented on Abbott's market-leading XIENCE V(R) stent 562
10 Abbott Reports 16 Percent Earnings Growth in First Quarter 468
11 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium 1021
12 The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent 750
13 Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics 478
14 Abbott Receives EC Clearance on Acquisition of Advanced Medical Optics 515
15 Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter 602
16 Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection 625
17 Abbott Announces Earnings Guidance for 2009 387
18 Abbott Opens New Research Facility and Pilot Plant in Ludwigshafen 458
19 Abbott’s HUMIRA® (adalimumab) Approved in the European Union 839
 
Bookmark and Share

Banner